news
Experimental drug targets gene driving severe seizures in children
Researchers at the Fralin Biomedical Research Institute are developing a targeted KCNT1 inhibitor that has shown early promise in reducing seizures in preclinical models.
List view / Grid view
In Vivo
news
Dual-action therapy clears MDR bacteria in preclinical models
Centauri Therapeutics has published data showing that CTX-09’s ability effectively clears drug-resistant Gram-negative bacteria through a novel dual mechanism, marking a promising development for new infection therapies.
article
A global push for better animal welfare in research
What does ethical research look like in drug discovery today? In this interview, Charles River’s Executive Director of Global Animal Welfare shares how global standards, the 3Rs and her own path as a woman in STEM are shaping efforts to reduce animal use in science.
news
New plasma therapy fights aggressive soft tissue cancer
Researchers at Osaka Metropolitan University have found that plasma-activated medium (PAM) significantly reduces synovial sarcoma tumour growth in both lab and animal models, offering a promising new approach for treating this rare and aggressive cancer.
news
Lab-grown liver breakthrough could speed up drug development
Scientists have developed lab-grown liver organoids with functional zonation, a discovery that brings regenerative medicine a step closer to personalised, transplant-free liver therapy.
news
Tessera’s gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
news
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
news
Damaged small intestine repaired with hPSC-derived organoids
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
Identifying disease-promoting microenvironments in AKI
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.
news
New DNA aptamer stabilises atherosclerosis plaques
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
news
Enhancing drug discovery using genetically diverse mouse models
Researchers suggest that integrating genetically diverse mouse models with cell-based assays will better replicate human diseases.
news
Development of a new and promising antimalarial agent
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
news
Novel inhibitor developed to combat HER2-positive breast cancer
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
